Chunfang (Vicky) Gu serves as Senior Director of Finance at Adagene. Reporting to the Chief Financial Officer, Ms. Gu manages its finance team, and plays a key role in the company’s financial and capital market transactions. She played an important role in the successful completion of its Series C-1 in 2018, and Series C-2 and Series C-3 in 2019, as well as its initial public offering on Nasdaq in February 2021. In addition, Ms. Gu made significant contribution to establish the company’s employee incentive plans.
Ms. Gu has over 17 years of experience in financial management with exposure to audit firm and multinational corporations. Prior to joining Adagene, Ms. Gu worked in the finance and accounting department at several companies including Sulzer Pumps, Bluescope Steel and Mercury Marine, where she gained extensive experience in financial reporting, financial planning and analysis, internal control and compliance, tax planning, as well as project management.
Ms. Gu received her Master of Business Administration degree from Xiamen University in 2016 and bachelor’s degree in accounting from Tianjin University of Commerce in 2003.
Ling (Jolin) Zhou has served as our Head of Human Resources since October 2019. Before joining Adagene, Ms. Zhou served as the HR director of Asia Pacific at Tekni-Plex, where she was responsible for the HR initiatives including strategic planning and business support from May 2010 to August 2019. Between October 2004 and May 2010, Ms. Zhou served as the HR supervisor at Suzhou Capsugel Ltd., a division of Pfizer, where she was responsible for all HR functions and personnel training. Ms. Zhou received her bachelor’s degree in law from South-Central University for Nationalities in 2003. She is a DDI Certified Trainer.
Dr. Ai Li is Head of Biometrics at Adagene. He has over 14 years of experience as a biostatistician and lead of biometrics.
Dr. Li has extensive experience in both early and late phase studies over various oncology indications. He has worked on small molecule and biologics drugs, T-cell therapy, and an oncolytic virus. He previously worked at QED Therapeutics leading the biometrics team for the filing of a targeted cancer therapy, which has been approved in the U.S., Canada, and Australia. Before QED, he worked for Novartis, Amgen, Puma Biotechnology and Atara Biotherapeutics, and was the key member of two successful NDA/BLA filings, including the first oncolytic virus approved for use in the U.S. and European Union. Dr. Li has more than 30 publications and received more than 3000 citations.
Dr. Li received his Ph.D. in Biostatistics at UCLA.
Dana Hu-Lowe, Ph.D., is the VP of Global Product Team Leadership of Adagene. Dr. Hu-Lowe has more than 20 years of experience in oncology drug discovery, pharmacology, translational research, and clinical development, with over seven years of experience in project and strategic alliance management, and leadership of both preclinical and clinical product programs.
Before joining Adagene, Dr. Hu-Lowe was the Executive Director and Global Product Team Lead (GPTL) for enzolvantinib and TPX-0046 at Turning Point Therapeutics, responsible for early clinical development of the assets. Before that, Dr. Hu-Lowe was the Senior Director of Strategic Alliance and Program management at Wellspring Biosciences Inc., where she successfully managed both internal discovery and IND-enabling programs, as well as strategic partnership with pharma and academic research entities. Prior to this, Dr. Hu-Lowe spent over 12 years at Pfizer Oncology as a functional group leader (angiogenesis and TME) and research project leader, where she led multiple cross-functional teams advancing programs from preclinical to IND submission/clearance and into clinical development. During her Pfizer tenure, Dr. Hu-Lowe also served as the translational research representative to clinical development programs, directly contributed to the NDA and approvals of axitinib (Inlyta™) and sunitinib (Sutent™) by the U.S. FDA, and was a recipient of the prestigious Pfizer “Career Achievement Award”.
Dr. Hu-Lowe received her undergraduate degree in Chemistry from BNU of China, Ph.D. in Biochemistry from the University of Mississippi and completed her post-doctoral training and academic research track at the Scripps Research Institute and the Burnham Cancer Institute (now the Sanford Burnham Prebys Medical Discovery Institute) with a focus on integrins, extracellular metrix, and angiogenesis.
Jiping Zha, M.D., Ph.D. is our Executive Vice President of Clinical Development. Dr. Zha is a physician scientist with over 20 years of formative experience in both academia and biotech industry. He received Howard Temin Award from National Cancer Institute. Previously, he was also an instructor at Harvard Medical School and an Assistant Professor at the University of Texas Southwestern Medical Center at Dallas. He has extensive experience in disease biology, drug discovery, translational sciences and clinical development, and successfully led multiple small and large molecule programs from IND-enabling stages to clinical testing. He also played key roles in the development and execution of multiple biomarker/companion diagnostic programs at Genentech and MedImmune, and was a development team lead and clinical lead for a phase 1/2 solid tumor program at NGM Biopharmaceuticals.
Dr. Zha has served multiple leadership positions, which include the discovery/diagnostic/translational science team leaderships at Genentech and MedImmune, SVP of Drug Discovery Technologies and VP of Cancer Biology at Crown Bioscience, and most recently as executive director of Translational Sciences at NGM Biopharmaceuticals. He has over 40 publications in high-impact scientific journals, such as Cell, Science and Nature, and authored multiple patents.
Dr. Zha received his M.D. from Shanghai Medical University, and Ph.D. in Microbiology and Immunology from the University of Tennessee Health Science Center. He completed his anatomic pathology residency training at Washington University School of Medicine and Brigham and Women’s Hospital. Dr. Zha is a licensed physician in the State of California and board-certified in Anatomic Pathology.
Ami Celeste Knoefler is the Vice President of Investor Relations and Corporate Communications, responsible for managing communications to support and optimize the long-term value of Adagene on behalf of all stakeholders. Ami has more than 25 years of global experience in pharmaceutical, biotech and medical technology communications, including positions at Ascendis Pharma, Jazz Pharmaceuticals, PDL BioPharma, Abgenix and Bristol-Myers Squibb.
Previously, she has led investor and corporate communications for PDL Biopharma and Abgenix, Inc., two antibody platform companies. Her career focus includes Corporate Communications, Product Communications, Patient Advocacy, and Investor Relations. She previously held roles in Global Communications at Ascendis Pharma, where she led corporate marketing, patient advocacy and product communications, and at Jazz Pharmaceuticals, where she led Corporate & Investor Relations activities during a period of transformation and sustained earnings growth.
Ami also founded her own company, Spark BioComm LLC, where she integrated communications and acted as strategic advisor covering investor, corporate, media, and medical communications for small and mid-cap clients.
Ami holds a B.S. from Boston University where she graduated magna cum laude with distinction in International Communications.
Wenlin Zeng, Ph.D., is the VP of Early Stage CMC. Dr. Zeng has over 20 years of experience in drug discovery and drug development in the biopharmaceutical industry.
Prior to joining Adagene, Dr. Zeng was the Senior Director of Upstream Process Development responsible for both early and late stage programs at Gilead Sciences, Inc. Prior to that, she was the Senior Director of Cell Line and Upstream Process Development at Forty-Seven Inc., where she was responsible for cell line, upstream process development and manufacturing for a number of programs, including magrolimab. Prior to Forty-Seven, Dr. Zeng held leadership positions at multiple biopharmaceutical companies, including NGM Bio, GSK, MedImmune, and Abgenix.
Dr. Zeng began her career in biopharmaceutical industry after completing her post-doctoral training at Stanford University. She earned her Ph.D. in Biochemistry from The University of Iowa and B.S. in Cell Biology from Wuhan University in China.
Mr. Peter Luo is our Co-Founder and has served as our Chief Executive Officer since November 2011 and Chairman of the Board of the Directors since February 2018. Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor (Nasdaq: XNCR) from July 1998 to August 2000. In September 2000, Dr. Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May 2006, Dr. Luo led the acquisition of Abmaxis Inc. by Merck & Co. (NYSE: MRK), after which Dr. Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck & Co. Throughout his career, Dr. Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr. Luo received his bachelor’s degree in applied chemistry in technical physics from Peking University in 1986, master’s degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989, and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr. Luo also completed his postdoctoral research in protein folding at Stanford University in 1998.
Jin Shang, Ph.D., is the Senior Vice President of Global Regulatory Affairs at Adagene. She has more than 20 years of drug development experience in the biopharmaceutical industry.
Dr. Shang joined Adagene from AstraZeneca where she served as Director of Regulatory Affairs, Oncology. She provided global and US regulatory leadership for multiple oncology programs, including Koselugo®. Prior to AstraZeneca, Dr. Shang was Associate Director of Global Regulatory Strategy at Sun Pharma Advanced Research Company, where she led regulatory strategy development and implementation for multiple development programs for indications of oncology, ophthalmology, neurology, and dermatology. Prior to Sun Pharma, Dr. Shang was Director of Biology at Morphic Therapeutics, where she led the fibrosis biology team. Before Morphic, Dr. Shang worked at Merck Research Laboratories for twelve years on drug discovery and development in cardiometabolic diseases in a variety of positions of increasing responsibilities. She also worked at Lynx Therapeutics and Metabolex previously.
Dr. Shang began her career in the biopharmaceutical industry after obtaining her Ph.D. in Development Biology from Stanford University, and her bachelor’s degree in Cell Biology and Genetics from Peking University.
Songmao Zheng, Ph.D., is currently Vice President, Head of Clinical and Quantitative Pharmacology at Adagene, leading preclinical and clinical quantitative model-informed drug discovery and development. He joined Adagene as Associate VP of R&D in early 2021.
Previously, as Scientific Director/Group Leader at Janssen BioTherapeutics, Songmao guided the preclinical, translational, and early clinical PK/TE/PD characterization of numerous biologics across oncology, immunology, and other therapeutic areas. He was awarded the prestigious Philip B. Hofmann Research Scientist Award, the second highest recognition in Johnson & Johnson, given to researchers for “major contributions of leadership, original ideas and research leading toward development of a technology platform, process or better understanding of a scientific technical phenomenon”. As a recognized key member of the Janssen teams, he also received >25 J&J Leadership, Innovation Leadership, and Encore/Inspire awards.
Songmao has authored approximately 30 peer-reviewed publications (accumulative Impact Factor approximately 150) and book chapters, has presented in over 30 national and international conferences with 6 awards, and is named as co-inventor on approximately 10 patent filings. Currently, he serves as a Member of Scientific Program Committee of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), and an Editorial Board member for ASCPT’s peer-reviewed journals Clinical and Translational Science (CTS) and Clinical Pharmacology & Therapeutics (CPT), the flagship journal of ASCPT.
Songmao received his Ph.D. in Pharmaceutical Sciences from the University of Washington (UW), followed by postdoctoral training at the Center for Pharmacometrics & Systems Pharmacology (CPSP) in the Department of Pharmaceutics at the University of Florida (UF). He currently is appointed Affiliate Associate Professor at the UW and Courtesy Adjunct Assistant Professor at the UF. He is also serving as a Corporate Advisory Board Member at the UW School of Pharmacy. Songmao graduated from Sichuan University with a B.S. degree in Biological Sciences, during which time he was awarded a one-year honored exchange at the UW Department of Hematology. He received further training as an intern at Seattle Genetics and as an ORISE Fellow at US FDA.